Neurotech International Limited (ASX:NTI)

Market Cap	21.01M +5.3%
Revenue (ttm)	4.73M +93.7%
Net Income	-6.54M
EPS	-0.01
Shares Out	1.62B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	952,781
Open	0.0140
Previous Close	0.0140
Day's Range	0.0130 - 0.0140
52-Week Range	0.0100 - 0.0220
Beta	0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In fiscal year 2026, Neurotech International's revenue was 4.73 million, an increase of 93.68% compared to the previous year's 2.44 million. Losses were -6.54 million, -38.31% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error